Delivery Order SPE2DB20D3103-SPE2DB25FQ2B3
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,362.54 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 320-25 mg tablets (90-count) on August 18, 2025, with completion expected by August 19, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under an open contracting vehicle. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,182.88 to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Valsartan-HCZ 160-25 mg tablets in a quantity of 90 units. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 4, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $5,582.42 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-12.5 mg tablets (90-count) on August 19, 2025, with completion scheduled for August 20, 2025. This non-competitive delivery order utilizes firm fixed pricing and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that...
- The Defense Logistics Agency awarded a delivery order valued at $6,539.63 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-25 mg tablets in quantities of 90 units. The contract employs firm fixed price pricing and carries an ultimate completion date of August 25, 2025, just three days after the award date of August 22, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $36,196.14 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-12.5 mg tablets (90-count) on August 12, 2025, with completion targeted for August 13, 2025. This firm fixed-price delivery order was awarded without set-aside designation through competitive procedures and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Valsartan-HCTZ 320-25 mg tablets (90-count) valued at $5,573.64. This is a firm fixed-price delivery order with no set-aside designation, and the product is scheduled for delivery by July 29, 2025. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Valsartan-HCT 160-25 mg tablets (90-count) valued at $2,284.16, with an ultimate completion date of September 2, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle. The awardee, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a $2,581.62 delivery order to AmerisourceBergen Drug Corp for Valsartan-HCTZ 80-12.5 mg tablets (90-count supply) on February 13, 2025, with completion scheduled for February 14, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen is a major pharmaceutical distributor and healthcare solutions provider...
- The Defense Logistics Agency awarded a delivery order valued at $4,733.29 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 160-25 mg tablets (90-count bottles) under a firm fixed-price contract. The award was made on August 14, 2025, with an ultimate completion date of August 15, 2025, and represents a non-set-aside competitive procurement. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate office and primary...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,542.97 to AmerisourceBergen Drug Corp for Valsartan-HCTZ 320-25 mg tablets (90-count supply). This competitively awarded, firm fixed-price delivery order was issued on August 15, 2025, with an ultimate completion date of August 18, 2025. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate headquarters. As a child delivery order under a...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FQ2B3Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,139.90 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCTZ 320-25 mg tablets (90-count) on September 8, 2025, with an ultimate completion date of September 9, 2025. This competitively awarded, firm fixed-price delivery order is non-set-aside and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The order represents a single transaction under AmerisourceBergen Drug Corp's existing contract vehicle with DLA. This delivery order is issued under AmerisourceBergen Drug Corp's $999.99 billion Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), which runs through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is a critical federal vendor supplying a broad portfolio of medications and medical supplies to support Defense Health Agency and other government healthcare systems. The parent contract reflects DLA's Pharmaceutical Prime Vendor Global Program approach, which is structured to make multiple regional awards to enable flexible and comprehensive pharmaceutical support across military medical supply chains worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.1k | 9/8/25 |